A work published in the journal European Journal of Medicinal Chemistry and carried out by researchers from CIBER-BBN and University of Alcalá has shown the effectiveness of a new family of nanodrugs for treating prostate cancer.
Nanosystems act selectively and induce apoptosis, or cell death, in advanced prostate cancer tumor cells. These metallodendrimers (nanopharms) are composed of functionalized carbosilane metal structures and metals such as copper or ruthenium. These metals have demonstrated antitumor activity by preventing tumor cell proliferation and metastasis.
Studies conducted in mice showed a reduction of advanced prostate tumors of between thirty and forty percent.
In addition to this quality, they showed a reduction in the adhesion of tumor cells to collagen I, a type of collagen present in bone. This reduction also prevents bone metastasis.
Finally, the research team explains that it is a drug that can be eliminated through feces or urine, leaving a low concentration in the organs.
